175 related articles for article (PubMed ID: 35021095)
21. Trovafloxacin-induced replication stress sensitizes HepG2 cells to tumor necrosis factor-alpha-induced cytotoxicity mediated by extracellular signal-regulated kinase and ataxia telangiectasia and Rad3-related.
Beggs KM; Maiuri AR; Fullerton AM; Poulsen KL; Breier AB; Ganey PE; Roth RA
Toxicology; 2015 May; 331():35-46. PubMed ID: 25748550
[TBL] [Abstract][Full Text] [Related]
22. Thymidine rescues ATR kinase inhibitor-induced deoxyuridine contamination in genomic DNA, cell death, and interferon-α/β expression.
Sugitani N; Vendetti FP; Cipriano AJ; Pandya P; Deppas JJ; Moiseeva TN; Schamus-Haynes S; Wang Y; Palmer D; Osmanbeyoglu HU; Bostwick A; Snyder NW; Gong YN; Aird KM; Delgoffe GM; Beumer JH; Bakkenist CJ
Cell Rep; 2022 Sep; 40(12):111371. PubMed ID: 36130512
[TBL] [Abstract][Full Text] [Related]
23. Cotargeting of MEK and PDGFR/STAT3 Pathways to Treat Pancreatic Ductal Adenocarcinoma.
Sahu N; Chan E; Chu F; Pham T; Koeppen H; Forrest W; Merchant M; Settleman J
Mol Cancer Ther; 2017 Sep; 16(9):1729-1738. PubMed ID: 28619758
[TBL] [Abstract][Full Text] [Related]
24. Immunogenicity of small-cell lung cancer associates with STING pathway activation and is enhanced by ATR and TOP1 inhibition.
Li X; Li Y; Zhao Z; Miao N; Liu G; Deng L; Wei S; Hou J
Cancer Med; 2023 Feb; 12(4):4864-4881. PubMed ID: 35957613
[TBL] [Abstract][Full Text] [Related]
25. ATR inhibition sensitizes HPV
Leonard BC; Lee ED; Bhola NE; Li H; Sogaard KK; Bakkenist CJ; Grandis JR; Johnson DE
Oral Oncol; 2019 Aug; 95():35-42. PubMed ID: 31345392
[TBL] [Abstract][Full Text] [Related]
26. ATR inhibition rewires cellular signaling networks induced by replication stress.
Wagner SA; Oehler H; Voigt A; Dalic D; Freiwald A; Serve H; Beli P
Proteomics; 2016 Feb; 16(3):402-16. PubMed ID: 26572502
[TBL] [Abstract][Full Text] [Related]
27. Targeting the NPL4 Adaptor of p97/VCP Segregase by Disulfiram as an Emerging Cancer Vulnerability Evokes Replication Stress and DNA Damage while Silencing the ATR Pathway.
Majera D; Skrott Z; Chroma K; Merchut-Maya JM; Mistrik M; Bartek J
Cells; 2020 Feb; 9(2):. PubMed ID: 32085572
[TBL] [Abstract][Full Text] [Related]
28. Interleukin 35 Expression Correlates With Microvessel Density in Pancreatic Ductal Adenocarcinoma, Recruits Monocytes, and Promotes Growth and Angiogenesis of Xenograft Tumors in Mice.
Huang C; Li Z; Li N; Li Y; Chang A; Zhao T; Wang X; Wang H; Gao S; Yang S; Hao J; Ren H
Gastroenterology; 2018 Feb; 154(3):675-688. PubMed ID: 28989066
[TBL] [Abstract][Full Text] [Related]
29. MEK Inhibition Sensitizes Pancreatic Cancer to STING Agonism by Tumor Cell-intrinsic Amplification of Type I IFN Signaling.
Ghukasyan R; Liang K; Chau K; Li L; Chan C; Abt ER; Le T; Park JY; Wu N; Premji A; Damoiseaux R; Luu T; Labora A; Rashid K; Link JM; Radu CG; Donahue TR
Clin Cancer Res; 2023 Aug; 29(16):3130-3141. PubMed ID: 37195712
[TBL] [Abstract][Full Text] [Related]
30. Melittin inhibits tumor growth and decreases resistance to gemcitabine by downregulating cholesterol pathway gene CLU in pancreatic ductal adenocarcinoma.
Wang X; Xie J; Lu X; Li H; Wen C; Huo Z; Xie J; Shi M; Tang X; Chen H; Peng C; Fang Y; Deng X; Shen B
Cancer Lett; 2017 Jul; 399():1-9. PubMed ID: 28428074
[TBL] [Abstract][Full Text] [Related]
31. ATM Deficiency Generating Genomic Instability Sensitizes Pancreatic Ductal Adenocarcinoma Cells to Therapy-Induced DNA Damage.
Perkhofer L; Schmitt A; Romero Carrasco MC; Ihle M; Hampp S; Ruess DA; Hessmann E; Russell R; Lechel A; Azoitei N; Lin Q; Liebau S; Hohwieler M; Bohnenberger H; Lesina M; Algül H; Gieldon L; Schröck E; Gaedcke J; Wagner M; Wiesmüller L; Sipos B; Seufferlein T; Reinhardt HC; Frappart PO; Kleger A
Cancer Res; 2017 Oct; 77(20):5576-5590. PubMed ID: 28790064
[TBL] [Abstract][Full Text] [Related]
32. In Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer.
Carugo A; Genovese G; Seth S; Nezi L; Rose JL; Bossi D; Cicalese A; Shah PK; Viale A; Pettazzoni PF; Akdemir KC; Bristow CA; Robinson FS; Tepper J; Sanchez N; Gupta S; Estecio MR; Giuliani V; Dellino GI; Riva L; Yao W; Di Francesco ME; Green T; D'Alesio C; Corti D; Kang Y; Jones P; Wang H; Fleming JB; Maitra A; Pelicci PG; Chin L; DePinho RA; Lanfrancone L; Heffernan TP; Draetta GF
Cell Rep; 2016 Jun; 16(1):133-147. PubMed ID: 27320920
[TBL] [Abstract][Full Text] [Related]
33. Targeting DNA damage response pathways to activate the STING innate immune signaling pathway in human cancer cells.
Wayne J; Brooks T; Landras A; Massey AJ
FEBS J; 2021 Aug; 288(15):4507-4540. PubMed ID: 33529438
[TBL] [Abstract][Full Text] [Related]
34. CD147 promotes DNA damage response and gemcitabine resistance via targeting ATM/ATR/p53 and affects prognosis in pancreatic cancer.
Zhou Y; Zheng M; Liu Z; Yang H; Zhu P; Jiang JL; Tang J; Chen ZN
Biochem Biophys Res Commun; 2020 Jul; 528(1):62-70. PubMed ID: 32456796
[TBL] [Abstract][Full Text] [Related]
35. ATR inhibition facilitates targeting of leukemia dependence on convergent nucleotide biosynthetic pathways.
Le TM; Poddar S; Capri JR; Abt ER; Kim W; Wei L; Uong NT; Cheng CM; Braas D; Nikanjam M; Rix P; Merkurjev D; Zaretsky J; Kornblum HI; Ribas A; Herschman HR; Whitelegge J; Faull KF; Donahue TR; Czernin J; Radu CG
Nat Commun; 2017 Aug; 8(1):241. PubMed ID: 28808226
[TBL] [Abstract][Full Text] [Related]
36. ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D.
Komura K; Yoshikawa Y; Shimamura T; Chakraborty G; Gerke TA; Hinohara K; Chadalavada K; Jeong SH; Armenia J; Du SY; Mazzu YZ; Taniguchi K; Ibuki N; Meyer CA; Nanjangud GJ; Inamoto T; Lee GM; Mucci LA; Azuma H; Sweeney CJ; Kantoff PW
J Clin Invest; 2018 Jul; 128(7):2979-2995. PubMed ID: 29863497
[TBL] [Abstract][Full Text] [Related]
37. Re-purposing clinical kinase inhibitors to enhance chemosensitivity by overriding checkpoints.
Beeharry N; Banina E; Hittle J; Skobeleva N; Khazak V; Deacon S; Andrake M; Egleston BL; Peterson JR; Astsaturov I; Yen TJ
Cell Cycle; 2014; 13(14):2172-91. PubMed ID: 24955955
[TBL] [Abstract][Full Text] [Related]
38. ZEB1 inhibition sensitizes cells to the ATR inhibitor VE-821 by abrogating epithelial-mesenchymal transition and enhancing DNA damage.
Song N; Jing W; Li C; Bai M; Cheng Y; Li H; Hou K; Li Y; Wang K; Li Z; Liu Y; Qu X; Che X
Cell Cycle; 2018; 17(5):595-604. PubMed ID: 29157079
[TBL] [Abstract][Full Text] [Related]
39. JTC801 Induces pH-dependent Death Specifically in Cancer Cells and Slows Growth of Tumors in Mice.
Song X; Zhu S; Xie Y; Liu J; Sun L; Zeng D; Wang P; Ma X; Kroemer G; Bartlett DL; Billiar TR; Lotze MT; Zeh HJ; Kang R; Tang D
Gastroenterology; 2018 Apr; 154(5):1480-1493. PubMed ID: 29248440
[TBL] [Abstract][Full Text] [Related]
40. Induction of cell death in pancreatic ductal adenocarcinoma by indirubin 3'-oxime and 5-methoxyindirubin 3'-oxime in vitro and in vivo.
Sano M; Ichimaru Y; Kurita M; Hayashi E; Homma T; Saito H; Masuda S; Nemoto N; Hemmi A; Suzuki T; Miyairi S; Hao H
Cancer Lett; 2017 Jul; 397():72-82. PubMed ID: 28347789
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
